Real-World Evidence Acceptability and Use in Breast Cancer Treatment Decision-Making in the United States: Call-to-Action from a Multidisciplinary Think Tank

Blue Matter team members Chirag Ghai and Cameron Wong provided writing and editorial support for this paper by Khozin, S., Dreyer, N.A., Galante, D. et al. (2025).

ABSTRACT

Complementing randomized controlled trials, real-world evidence (RWE) from observational analyses can extend clinical insights in oncology. While healthcare stakeholders have published rigorous RWE frameworks and resources, a multidisciplinary think tank was established to further advance acceptance and use of RWE in treatment decision-making, with the focus on breast cancer (while recognizing relevance in oncology more broadly). Members discussed perceptions of RWE from a clinical perspective, across domains of data, methodology, and mindset, and “calls-to-action” for stakeholders. Agreement was reached on a primary “call-to-action,” to develop clinically-relevant, patient-informed, real-world endpoints, and secondary “calls-to-action”: establish a multidisciplinary consensus forum; publish examples of unique RWE value; build upon existing frameworks and resources; and tailor an approach for exhibiting utility to guideline bodies.

Access the full paper here or get a PDF version here.